Grifols (GRFS) Shares Outstanding (Weighted Average) (2010 - 2025)
Grifols (GRFS) reported Shares Outstanding (Weighted Average) of $792.1 million for Q4 2025, up 9.07% on a YoY basis from $726.3 million in Q4 2024, and up 9.07% quarter-over-quarter from $726.3 million in Q4 2024.
Grifols (GRFS) Shares Outstanding (Weighted Average) (2010 - 2025) Analysis & Trends
Grifols has reported Shares Outstanding (Weighted Average) for 16 years, with the latest figure at $792.1 million in Q4 2025.
- For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 9.07% year-over-year to $792.1 million; the trailing twelve-month figure through Dec 2025 stood at $792.1 million (up 9.07% YoY), and the FY2025 full-year result was $792.1 million, up 16.55% from the prior year.
- Shares Outstanding (Weighted Average) for Q4 2025 stood at $792.1 million, up from $726.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $792.1 million in Q4 2025, with the low at $122.0 million in Q4 2022.
- Historically, Shares Outstanding (Weighted Average) has averaged $630.3 million across 5 years, with a median of $731.4 million in 2023.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) slumped 84.35% — and 2023, when it surged 499.36%.
- Grifols' Shares Outstanding (Weighted Average) stood at $779.7 million in 2021, then tumbled by 84.35% to $122.0 million in 2022, then surged by 499.36% to $731.4 million in 2023, then decreased by 0.7% to $726.3 million in 2024, then increased by 9.07% to $792.1 million in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $792.1 million (Q4 2025), $726.3 million (Q4 2024), and $731.4 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 1,818,692.66 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 894.50 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.41 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 1.77 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 2.47 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 540.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.24 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 5.69 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.04 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | 792.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 792.15 Mn |
| Dec 31, 2024 | 726.29 Mn |
| Dec 31, 2023 | 731.38 Mn |
| Dec 31, 2022 | 122.03 Mn |
| Dec 31, 2021 | 779.68 Mn |
| Dec 31, 2020 | 817.33 Mn |
| Sep 30, 2020 | 139,706.71 |
| Mar 31, 2020 | 132,035.52 |
| Dec 31, 2019 | 758.35 Mn |
| Sep 30, 2019 | 133,086.96 |
| Dec 31, 2018 | 781.52 Mn |
| Sep 30, 2018 | 139,114.90 |
| Jun 30, 2018 | 142,740.73 |
| Mar 31, 2018 | 146,937.44 |
| Dec 31, 2017 | 805.60 Mn |
| Jun 30, 2017 | 450.82 |
| Dec 31, 2016 | 460.10 Mn |
| Sep 30, 2016 | 658.55 |
| Jun 30, 2016 | 440.65 |
| Dec 31, 2015 | 749.25 Mn |